Please assess the completion status of the following clinical trial:

Trial Title: The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females, age above 36 months ;~* Adults, parent(s) or guardians are able to understand and sign informed consent for participation;~* Participants or guardians are able to attend all planned clinical appointment and obey and follow all study instructions;~* Infants no vaccinated with influenza or other preventive biologicals in recent 7 days;~* Axillary temperature ≤37℃.~Exclusion Criteria:~* Have medical record of participants or their family on allergy and egg, convulsion, falling sickness, encephalopathy and psychopathy;~* Low platelet or bleeding disorder do not allow vaccination into the muscle;~* Have damaged or lower immunological function;~* Received blood, plasma or immunoglobulin treatment since birth;~* Have inborn abnormality, develop obstacles or clinical diagnostic serious chronic ( Down Syndrome, diabetes, sickle cell anemia or neural Guillain-Barre Syndrome );~* Have or be doubtful of following diseases: respiratory system diseases, acute infection or active chronic, cardiovascular diseases, liver and kidney diseases, skin diseases, HIV.

- Gender: ALL
- Minimum Age: 36 Months
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Influenza Virus Vaccine (Type: EXPERIMENTAL): Influenza Virus Vaccine（no Preservative ) 0.5ml intramuscular injections
- Influenza Virus Vaccine(Preservative) (Type: EXPERIMENTAL): Influenza Virus Vaccine（add Preservative ) 0.5ml intramuscular injections

Based on this trial design, predict the completion outcome and termination type (if applicable).